Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study

van der Heijde D, Gensler LS, Maksymowych WP, Landewe R, Rudwaleit M, Bauer L, Kumke T, Kim M, Auteri SE, Hoepken B, Deodhar A (2022)
RMD Open 8(1): e002138.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
van der Heijde, Desiree; Gensler, Lianne S.; Maksymowych, Walter P.; Landewe, Robert; Rudwaleit, MartinUniBi; Bauer, Lars; Kumke, Thomas; Kim, Mindy; Auteri, Simone Emanuele; Hoepken, Bengt; Deodhar, Atul
Abstract / Bemerkung
Background 52-week results from C-axSpAnd demonstrated the safety and efficacy of certolizumab pegol (CZP) in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation (sacroiliitis on MRI and/or elevated C-reactive protein levels). Long-term safety and clinical outcomes, including MRI assessments, are evaluated up to 3 years for CZP-treated patients with nr-axSpA. Methods C-axSpAnd was a phase 3 study comprising a 1-year double-blind, placebo-controlled period and 2-year open-label safety follow-up extension (SFE). At baseline, 317 patients were randomised 1:1 to placebo or CZP 200 mg every 2 weeks. Patients completing the double-blind phase who enrolled into the SFE received open-label CZP for an additional 104 weeks. Long-term safety and clinical outcomes are reported to Week 156. Continuous outcomes are presented as observed case (OC) and dichotomous outcomes as OC and with non-responder imputation. Results 243/317 (76.7%) patients entered the SFE, during which 149 (61.3%) experienced Al treatment-emergent adverse event (TEAE); 15 (3.3/100 patient-years) experienced serious TEAEs. Continuous outcome scores (including Ankylosing Spondylitis Disease Activity Score [ASDAS]: 1.8; Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]: 2.7) at Week 52 were maintained at Week 156 (ASDAS: 1.8; BASDA1: 2.6) for the initial CZP-randomised group. Mean SPARCC MRI sacroiliac joint inflammation scores for these patients decreased at Week 52 (baseline: 7.6; Week 52: 1.7), remaining low at Week 156 (2.4). Conclusions CZP treatment was well tolerated up to 3 years, with no new safety signals versus previous reports. Clinical outcomes achieved after 1 year were sustained to 3 years.
Erscheinungsjahr
2022
Zeitschriftentitel
RMD Open
Band
8
Ausgabe
1
Art.-Nr.
e002138
eISSN
2056-5933
Page URI
https://pub.uni-bielefeld.de/record/2962214

Zitieren

van der Heijde D, Gensler LS, Maksymowych WP, et al. Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. RMD Open. 2022;8(1): e002138.
van der Heijde, D., Gensler, L. S., Maksymowych, W. P., Landewe, R., Rudwaleit, M., Bauer, L., Kumke, T., et al. (2022). Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. RMD Open, 8(1), e002138. https://doi.org/10.1136/rmdopen-2021-002138
van der Heijde, D., Gensler, L. S., Maksymowych, W. P., Landewe, R., Rudwaleit, M., Bauer, L., Kumke, T., Kim, M., Auteri, S. E., Hoepken, B., et al. (2022). Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. RMD Open 8:e002138.
van der Heijde, D., et al., 2022. Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. RMD Open, 8(1): e002138.
D. van der Heijde, et al., “Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study”, RMD Open, vol. 8, 2022, : e002138.
van der Heijde, D., Gensler, L.S., Maksymowych, W.P., Landewe, R., Rudwaleit, M., Bauer, L., Kumke, T., Kim, M., Auteri, S.E., Hoepken, B., Deodhar, A.: Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. RMD Open. 8, : e002138 (2022).
van der Heijde, Desiree, Gensler, Lianne S., Maksymowych, Walter P., Landewe, Robert, Rudwaleit, Martin, Bauer, Lars, Kumke, Thomas, Kim, Mindy, Auteri, Simone Emanuele, Hoepken, Bengt, and Deodhar, Atul. “Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study”. RMD Open 8.1 (2022): e002138.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 35296532
PubMed | Europe PMC

Suchen in

Google Scholar